Glaucoma is a chronic progressive optic neuropathy characterised by progressive loss of retinal ganglion cells, which manifests clinically with loss of optic disc neuroretinal rim tissue, defects in the retinal nerve fiber layer, and deficits on functional visual field testing ([@b16-co-2-15]).

In the United States, glaucoma is the second leading cause of blindness in the general population, and the leading cause of blindness in black patients. The pathogenesis of glaucomatous optic neuropathy remains incompletely understood. While elevated intraocular pressure (IOP) is a clear risk factor, vascular insufficiency and abnormal autoregulation of the optic nerve circulation have been hypothesized to play a significant role in the development and progression of glaucoma ([@b24-co-2-15]; [@b19-co-2-15]; Sossi and Anderson 1983). Primary open-angle glaucoma (POAG) is the most common form of glaucoma in the United States. The number of people with POAG worldwide in the year 2000 has been estimated at nearly 66.8 million, with 6.7 million having bilateral blindness ([@b45-co-2-15]).

The goal of glaucoma treatment is to reduce the intraocular pressure to a level that prevents or minimizes the progressive loss of vision ([@b25-co-2-15]; [@b21-co-2-15]; [@b51-co-2-15]; [@b1-co-2-15]; [@b30-co-2-15]).Three modalities of treatment are available including: medical therapy, laser surgery and conventional incisional surgery. Despite continued advances in laser and incisional surgery, medical therapy continues to be the primary means by which IOP is controlled ([@b48-co-2-15]).

The current standard of management for the newly diagnosed POAG patient is to start topical medication ([@b3-co-2-15]). Monotherapy with a single medication is usually tried first; however, many patients need more than one medication to lower IOP sufficiently to prevent progression. Available topical medications include: beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogues, and miotics.

Beta-blockers are highly effective in treating glaucoma ([@b58-co-2-15]; [@b7-co-2-15]; [@b46-co-2-15]; Ritch et al 1978; [@b42-co-2-15]; [@b36-co-2-15]) and were initially considered first line treatment. They reduce IOP by inhibiting aqueous humour production ([@b14-co-2-15]). Although they are usually well tolerated and are commonly used as monotherapy, they do have both local and systemic side effects. Local side effects include hyperemia of the conjunctiva, burning sensation, superficial punctuate keratitis and reduced tear flow ([@b55-co-2-15]). Systemic side effects, which are of more concern, may be induced by blocking the β~1~-adrenoceptors of the heart resulting in bradycardia, arrhythmia, congestive heart failure and syncope by Adam-stokes syndrom ([@b41-co-2-15]; [@b39-co-2-15]). Furthermore, blocking the β~2~-adrenoceptors of the bronchioles may cause bronchospasm in patients with chronic obstructive pulmonary disease or asthma ([@b47-co-2-15]).

Topical carbonic anhydrase inhibitors (CAIs) lower IOP by decreasing aqueous production ([@b38-co-2-15]). The most frequent side effects of CAIs include burning sensation, ocular discomfort, superficial punctuate keratitis and allergic conjunctivitis ([@b53-co-2-15]). CAIs also may impair the corneal endothelial pump function, thus causing corneal decompansation in predisposed patients ([@b31-co-2-15]).

Prostaglandin analogues are now considered the first line of treatment in POAG ([@b12-co-2-15]). The reduction of IOP by prostaglandin analogues is based on an increase in trabecular and uveoscleral outflow ([@b40-co-2-15]). While no systemic side effects have been reported with prostaglandins, local side effects include conjunctival hyperemia, stinging, burning sensation, punctuate keratitis, increased iris pigmentation, as well as cystoid macular edema in pseudophakic patients ([@b11-co-2-15]; [@b49-co-2-15]; [@b6-co-2-15]).

In some patients, IOP is not adequately controlled by monotherapy. In those refractory patients, where more efficacy is required, shifting to another medication or adding a second medication is indicated. The complimentary action between two drugs often serves as the basis for combination medications.

β-blockers can be combined well with miotics, topical CAIs, brominidine, and prostaglandin analogues. The efficacy of combining β-blockers with pilocarpine has been shown in various studies ([@b29-co-2-15]; [@b27-co-2-15]). The ocular side effects of pilocarpine include inducing myopia, headache, blurred vision, conjunctival hyperaemia, lens opacities and retinal detachments in predisposed patients ([@b35-co-2-15]; [@b43-co-2-15]), limiting its usefulness.

One avenue of delivering a second medication is through a fixed combination medication that has the advantage of providing two medicines within one drop. Such a product potentially reduces confusion from multiple bottles, aids compliance, lowers patient costs, and helps eliminate potential washout effects ([@b20-co-2-15]). In addition; safety might be theoretically increased by using a fixed combination product, which limits the exposure to benzalkonium chloride, a preservative in most eye drops that has demonstrated significant corneal epithelial toxicity that is dose dependent.

Topical CAIs are complimentary in ocular hypotensive efficacy when combined with β-blockers ([@b28-co-2-15]). Dorzolamide/timolol fixed combination (DTFC) was found to be as effective as the concomitant administration of its components in reducing IOP and has also simplified the therapy for patients needing these two medications ([@b8-co-2-15]). DTFC twice daily provided better IOP control than prostaglandin analogues once daily ([@b44-co-2-15]). For patients with pseudoexofoliation glaucoma (PXG), diurnal fluctuation of IOP is higher than in patients with POAG ([@b32-co-2-15]). Because damage to the optic nerve might be associated with fluctuations in IOP, a drug that consistently controls IOP throughout the diurnal curve may be an important choice for the medical treatment of refractory glaucomas such as PXG ([@b5-co-2-15]). In addition dorzolamide has been reported to increase blood flow in animal models and in healthy and glaucomatous patients ([@b22-co-2-15]; [@b26-co-2-15]). Several other studies have suggested that dorzolamide enhances ocular blood flow, including studies investigating the choroid ([@b23-co-2-15]) and the retrobulbar vessels ([@b37-co-2-15]).

Fixed combination brimonidine/timolol provides a combination of a β-blocker that reduces IOP by inhibiting aqueous production ([@b14-co-2-15]) and brimonidine, an alpha-adrenergic receptor agonist that has a dual mechanism of action:increasing uveoscleral outflow and reducing aqueous production.

Another potentially useful fixed combination is β-blocker to prostaglandin analogue, which has proven to be effective in controlling IOP in refractory patients ([@b56-co-2-15]). The mechanism of action of prostaglandin analogues is complimentary to the IOP lowering mechanism of β-blockers. Available lipid/timolol combinations (latanoprost/timolol and travoprost/timolol), have a similar complementary mechanism of action ([@b54-co-2-15]).

The latanoprost/timolol fixed combination dosed in the evening demonstrated a lower absolute IOP level at each time point and for 24- hours curve. Also, the maximum, minimum, and range of pressure were lower with the latanoprost/timolol fixed combination than with either drug alone ([@b2-co-2-15]). Adverse events included conjunctival hyperemia, ocular stinging and itching were observed frequently with the latanoprost/timolol fixed combination (Shen et al 2004).

Another new fixed combination is bimatoprost 0.03% or 0.3 mg/mL + timolol 0.5% or 5 mg/mL. Bimatoprost is a synthetic prostamide, structurally related to prostaglandin F (PGF) that does not act through any known prostaglandin receptors. It reduces intraocular pressure by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.

Timolol maleate is a non-selective adrenoreceptor antagonist that does not have significant intrinsic sympathomi-metic activity or membrane stabilizing activies. Blocking the beta-adrenoreceptors results in reduction of the intracellular second messenger, cAMP, believed to be involved in aqueous humour dynamics. Timolol does not have any effect on the outflow mechanism and exerts its effect on IOP by reducing aqueous humour production ([@b57-co-2-15]). Timolol 0.5% was selected as the preferred dose in the bimatoprost/ timolol fixed combination product, as the 0.25% concentration is considered to be suboptimal in the poorly controlled patient. In addition, the use of timolol 0.5% once-daily has been shown to provide a beneficial effect on IOP over a 24-hour period, an effect that was less pronounced with 0.25% concentration ([@b59-co-2-15]).

Studies have shown that bimatoprost/timolol fixed combination was rapidly absorbed and distributed into ocular tissues in close contact with the administration site. This concentration was highest in the iris and ciliary body which are the sites of pharmacological action. The pharmacokinetic parameters of bimatoprost/timolol fixed combination were similar with either single or combination treatment ([@b18-co-2-15]).

Systemic absorption of topical administration is well known. As expected, bimatoprost and timolol were detected systemically following ocular instillation. Systemic concentrations of bimatoprost and timolol are slightly lower when administered in combination versus single administration. Differences in metabolism of the two drugs suggest that they will not affect or alter one another ([@b18-co-2-15]).

For a fixed combination medication to be truly clinically advantageous, it must increase efficacy beyond each of its individual components given as monotherapy without decreasing safety ([@b17-co-2-15]). [@b9-co-2-15], reported that the combination was effective, lowering mean IOP from baseline by up to 9.6 mmHg, and clinically and statistically superior to each constituent as judged by the overall criterion of \>20% reduction in mean diurnal IOP, and maintaing the mean diurnal IOP below 18 mmHg at all visits. Also the reduction in IOP with the combination was numerically greater than for either active component and statically significant at most of the time points and visits.

As regards the safety of the combination, there were no signs or symptoms of intolerance and the incidence of conjunctival hyperemia was clinically and statistically less significant than each of the two components separately. The reason for the decreased incidence of conjunctival hyperemia is not clear. One possible explanation is that the α~1~-adrenoceptor agonistic effects of endogenous cat-echolamines, now unopposed by β~2~-adrenoceptor agonistic effects due to blockade by the timolol. Another explanation is that the antagonism of β~2~-adrenoceptors by timolol could diminish the production of nitric oxide ([@b4-co-2-15]), a mediator of bimatoprost-associated hyperemia ([@b13-co-2-15]). Irrespective of the mechanism, the conjunctival hyperemia associated with bimatoprost is non-inflammatory ([@b34-co-2-15]).

Actually the fixed combination of bimatoprost and timolol was clinically and statistically significantly more effective than either of its active constituents for patients with refractory glaucoma, for those patients requiring two or more ocular hypotensive medications, this single-bottle, fixed combination represents a convenient, therapeutic advantage over separate bottles. Also it represents a reduction in the number of drops per day that is required for the patient to instill. An established washout effect resulting from rapid sequence instillation of two medications requires that patients wait approximately 5 minutes between eye drops ([@b15-co-2-15]). Bimatoprost/timolol fixed combination offers a reduced time commitment for drop instillation and the potential for greater efficacy by eliminating the washout effect. Bimatoprost/timolol fixed combination offers cost and time savings, which may enhance compliance; also reducing the amount of preservative applied to the eye, will improve tolerability and may also favorably improve eventual surgical outcomes in patients who might require filtering procedures ([@b33-co-2-15]; [@b10-co-2-15]).
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